	Boehringer Ingelheim	Axios International

Boehringer Ingelheim

The Boehringer Ingelheim corporation is headquartered in Ingelheim, Germany. Boehringer Ingelheim is a global business present in more than 60 nations. The company manufactures and markets human pharmaceuticals (prescription medicines, consumer healthcare products) and products for industrial customers (like chemicals and biopharmaceuticals) and animal health. Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents.

VIRAMUNE® (nevirapine) is a product of original research done at Boehringer Ingelheim. VIRAMUNE® was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti- HIV drugs. Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor (NPPI) tipranavir in phase III clinical trials, and recently acquired the nucleoside analogue (NRTI) MIV-310 currently in phase II development. The company is involved in basic research and is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals.

•

For more information on Boehringer Ingelheim, please see www.boehringer-ingelheim.com/hiv .

Axios International

Axios is an organization dedicated to increasing access to health care in developing countries through innovative approaches. In the conception, design and implementation of a range of field programs globally, Axios has realized significant results in improving and expanding patient access to quality treatment and care, and validated new models and methodologies.

In its donation and access programs, Axios collaborates with a wide network of 450 benefiting institutions in 104 countries (December 2007) providing Axios with large intervention capabilities and unique access to comprehensive data and local knowledge.

For more information on Axios International, please see www.axios-group.com.